Compare 10X Genomics Inc (TXG) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? 10X Genomics Inc trades at $79.19 (market cap $10.07B), while Direxion Daily FTSE China Bull 3x Shares trades at $24.52 (market cap $560.32M). The key difference: 10X Genomics Inc is far larger — about 18× Direxion Daily FTSE China Bull 3x Shares's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| TXG | YINN | |
|---|---|---|
Market Cap | $10.07B | $560.32M |
Volume | 5,657,286 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $97.74 | $52.69 |
52-Week Low | $11.48 | $21.45 |
Typical Hold Time | 92 Days | 25 Days |
Enterprise Value | $9.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
YINN is trading at $23.56, down 2.97% with bearish technical indicators showing 18 sell signals versus 1 buy. The stock faces resistance at $24 with support at $23. Recent corporate actions include a $0.56 dividend scheduled for September 2026. Technical analysis indicates strong bearish momentum with moving averages unanimously negative.
The outlook remains challenging with bearish technical positioning and limited fundamental data availability. Key risks include market volatility and sector-specific headwinds. Investment opportunities may emerge if the stock stabilizes above support levels, but current momentum suggests continued downward pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
